Page 175 - Read Online

Hjalgrim et al. J Transl Genet Genom 2022;6:134-46 https://dx.doi.org/10.20517/jtgg.2021.46 Page 144

17. Hjalgrim H, Seow A, Rostgaard K, Friborg J. Changing patterns of Hodgkin lymphoma incidence in Singapore. Int J Cancer
2008;123:716-9. DOI PubMed
18. Macmahons B. Epidemiological evidence on the nature of Hodgkin’s disease. Cancer 1957;10:1045-54. DOI PubMed
19. MacMahon B. Epidemiology of Hodgkin’s disease. Cancer Res 1966;26:1189-201. PubMed
20. Cozen W, Katz J, Mack TM. Risk patterns of Hodgkin’s disease in Los Angeles vary by cell type. Cancer Epidemiol Biomarkers Prev
1992;1:261-8. PubMed
21. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international
data. Int J Cancer 1997;70:375-82. DOI PubMed
22. Gutensohn N, Cole P. Epidemiology of Hodgkin’s disease in the young. Int J Cancer 1977;19:595-604. DOI PubMed
23. Newell GR. Etiology of multiple sclerosis and Hodgkin’s disease. Am J Epidemiol 1970;91:119-22. DOI PubMed
24. Hjalgrim H. On the aetiology of Hodgkin lymphoma. Dan Med J 2012;59:B4485. PubMed
25. Epstein M, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1964;283:702-3. DOI
PubMed
26. Rostgaard K, Balfour HH Jr, Jarrett R, et al. Primary Epstein-Barr virus infection with and without infectious mononucleosis. PLoS
One 2019;14:e0226436. DOI PubMed PMC
27. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82. DOI PubMed
28. Poppema S, van Imhoff G, Torensma R, Smit J. Lymphadenopathy morphologically consistent with Hodgkin’s disease associated with
Epstein-Barr virus infection. Am J Clin Pathol 1985;84:385-90. DOI PubMed
29. Weiss LM, Strickler JG, Warnke RA, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin’s disease. Am J Pathology 1987;129:86-
91. PubMed PMC
30. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin’s disease and Ki-1-
positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989;74:810-6. PubMed
31. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin’s disease.
N Engl J Med 1989;320:502-6. DOI PubMed
32. Lee JH, Kim Y, Choi JW, Kim YS. Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin’s
lymphoma: a meta-analysis. Arch Med Res 2014;45:417-31. DOI PubMed
33. Levin LI, Chang ET, Ambinder RF, et al. Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin
lymphoma. Blood 2012;120:3750-5. DOI PubMed PMC
34. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-
Barr-virus-negative Hodgkin’s lymphoma. Lancet 2005;365:2216-24. DOI PubMed
35. Enciso-Mora V, Broderick P, Ma Y, et al. A genome-wide association study of Hodgkin’s lymphoma identifies new susceptibility loci
at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet 2010;42:1126-30. DOI PubMed PMC
36. Urayama KY, Jarrett RF, Hjalgrim H, et al. Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus
status-defined subgroups. J Natl Cancer Inst 2012;104:240-53. DOI PubMed PMC
37. Cozen W, Timofeeva MN, Li D, et al. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus.
Nat Commun 2014;5:3856. DOI PubMed PMC
38. Delahaye-Sourdeix M, Urayama KY, Gaborieau V, et al. A novel risk locus at 6p21.3 for Epstein-Barr virus-positive Hodgkin
lymphoma. Cancer Epidemiol Biomarkers Prev 2015;24:1838-43. DOI PubMed
39. Khankhanian P, Cozen W, Himmelstein DS, et al. Meta-analysis of genome-wide association studies reveals genetic overlap between
Hodgkin lymphoma and multiple sclerosis. Int J Epidemiol 2016;45:728-40. DOI PubMed PMC
40. Jarrett RF. Viruses and Hodgkin’s lymphoma. Ann Oncol 2002;13 Suppl 1:23-9. DOI PubMed
41. Desai S, Ansell SM. Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond. Leuk Lymphoma 2021;62:1795-804.
DOI PubMed
42. Cheson BD, Fisher RI, Barrington SF, et al; Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology
Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment
of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German
Hodgkin’s Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic
Lymphoma Study Group, Nordic Lymphoma Study Group, United Kingdom National Cancer Research Institute. Recommendations
for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin
Oncol 2014;32:3059-68. DOI PubMed PMC
43. Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:434-42. DOI
PubMed
44. Bröckelmann PJ, Specht L. Prognostic Factors. In: Engert A, Younes A, editors. Hodgkin lymphoma - a comprehensive review. Cham,
Switzerland: Springer Nature Switzerland AG; 2020. p. 145-70.
45. Allemani C, Sant M, De Angelis R, Marcos-Gragera R, Coebergh JW; EUROCARE Working Group. Hodgkin disease survival in
Europe and the U.S.: prognostic significance of morphologic groups. Cancer 2006;107:352-60. DOI PubMed
46. Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin’s lymphoma: a population-based
study. J Clin Oncol 2005;23:7604-13. DOI PubMed
47. Jarrett RF, Stark GL, White J, et al; Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group. Impact of tumor Epstein-
Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a
population-based study. Blood 2005;106:2444-51. DOI PubMed